Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06526858 · ClinicalTrials.gov registry record · NA
Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension
A NA study of Resistant Hypertension, sponsored by DeepQure.
- Recruiting
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 5
- Study locations
NCT06526858 is a NA study of Resistant Hypertension that is actively recruiting participants, run by DeepQure. The registered enrollment target is 15 participants, below the 3,412-participant average among 4 other Resistant Hypertension trials with a reported enrollment target (100% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT06526858, a NA study of Resistant Hypertension, is actively recruiting participants, sponsored by DeepQure.
- RECRUITING
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 5
- Study locations
Study Summary
HQ-HTN-G01 is a prospective, multicenter, single arm, open label, early feasibility study to evaluate initial safety and device design concept of "HyperQureTM RDN System", laparoscopic renal denervation therapy, in patients with resistant hypertension on three(3) or more antihypertensive medications
Conditions Studied
Interventions
- DEVICE HyperQureTM Renal Denervation (RDN) System:
Study Locations (5)
California
- University of California Irvine - Orange
- Stanford Health Care - Stanford
Florida
- University of Florida College of Medicine - Gainesville
Michigan
- Henry Forth Health - Detroit
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2024-11-21 |
| Est. Completion | 2029-03-20 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06526858
The ClinicalTrials.gov registry entry for NCT06526858 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,412-participant average among 4 other Resistant Hypertension trials with a reported enrollment target (100% lower). The listed sponsor is DeepQure, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Resistant Hypertension appearing as the primary indexed condition, and to 1 intervention - of which HyperQureTM Renal Denervation (RDN) System: is the first listed.
NCT06526858 reports 5 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT06526858 about?
NCT06526858 is a clinical study titled "Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension". HQ-HTN-G01 is a prospective, multicenter, single arm, open label, early feasibility study to evaluate initial safety and device design concept of "HyperQureTM RDN System", laparoscopic renal denervation therapy, in patients with resistant hypertension on three(3) or more antihypertensive medications
What is the current status of trial NCT06526858?
This trial is currently recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2024-11-21. Estimated completion is 2029-03-20.
What conditions does trial NCT06526858 study?
This clinical trial studies the following conditions: Resistant Hypertension.
What interventions are being tested in trial NCT06526858?
The interventions under investigation include: HyperQureTM Renal Denervation (RDN) System: (DEVICE).
Who is sponsoring clinical trial NCT06526858?
This trial is sponsored by DeepQure, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06526858 being conducted?
This trial has 5 study locations across California, Florida, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Resistant Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CALM- 2 - Controlling and Lowering Blood Pressure With the MobiusHD™
ACTIVE NOT RECRUITING · NA
-
Electronic Alert to Improve Testing For Primary Aldosteronism in Patients With Hypertension
ACTIVE NOT RECRUITING · NA
-
Allopurinol Improves Heart Function in African Americans With Resistant Hypertension
RECRUITING · Phase 2
-
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.